144.86
前日終値:
$144.16
開ける:
$142.99
24時間の取引高:
642.91K
Relative Volume:
0.72
時価総額:
$14.37B
収益:
$2.41B
当期純損益:
$305.80M
株価収益率:
49.11
EPS:
2.95
ネットキャッシュフロー:
$492.20M
1週間 パフォーマンス:
-4.93%
1か月 パフォーマンス:
+5.56%
6か月 パフォーマンス:
+21.96%
1年 パフォーマンス:
+17.89%
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
名前
Neurocrine Biosciences Inc
セクター
電話
(858) 617-7600
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences Inc
|
144.86 | 14.37B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
120.82 | 53.39B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 44.99B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.59 | 44.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.41 | 29.30B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
466.40 | 19.91B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | Citigroup | Buy |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-04-15 | アップグレード | Needham | Hold → Buy |
| 2025-04-14 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 再開されました | Citigroup | Neutral |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 繰り返されました | Mizuho | Neutral |
| 2023-07-24 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-30 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-02-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-09-26 | 開始されました | Wells Fargo | Equal Weight |
| 2022-06-06 | 再開されました | Jefferies | Buy |
| 2022-03-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-18 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Underperform |
| 2021-11-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 再開されました | Needham | Hold |
| 2021-08-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-05-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 開始されました | Raymond James | Outperform |
| 2020-09-30 | 開始されました | The Benchmark Company | Hold |
| 2020-08-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-29 | ダウングレード | Goldman | Buy → Neutral |
| 2020-06-09 | 開始されました | Wedbush | Outperform |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-24 | 開始されました | William Blair | Outperform |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-13 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-05 | 開始されました | Guggenheim | Neutral |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-02-06 | 繰り返されました | BofA/Merrill | Buy |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 開始されました | Goldman | Buy |
| 2018-11-21 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Neurocrine Biosciences Inc (NBIX) 最新ニュース
Is Neurocrine Biosciences Inc. (NB3) stock a buy for dividend portfolios2025 Big Picture & Technical Entry and Exit Alerts - newser.com
Why Neurocrine Biosciences Inc. stock remains resilientPortfolio Performance Report & Real-Time Stock Movement Alerts - newser.com
What makes Neurocrine Biosciences Inc. (NB3) stock appealing to growth investors2025 Sector Review & Low Risk High Win Rate Picks - newser.com
Can Neurocrine Biosciences Inc. stock weather global recessionEarnings Miss & Community Driven Trade Alerts - newser.com
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyJuly 2025 Fed Impact & Low Drawdown Investment Strategies - newser.com
Is Neurocrine Biosciences Inc. stock trading near support levelsJuly 2025 Rallies & Comprehensive Market Scan Reports - newser.com
Can Neurocrine Biosciences Inc. (NB3) stock beat analyst consensusTrade Volume Summary & Consistent Profit Alerts - newser.com
How Neurocrine Biosciences Inc. stock responds to policy changesWeekly Profit Report & Consistent Return Strategy Ideas - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock boost dividends furtherPortfolio Value Report & Real-Time Volume Analysis Alerts - newser.com
Is it time to cut losses on Neurocrine Biosciences Inc.Weekly Trend Recap & Technical Confirmation Alerts - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock attractive for dividend growthTake Profit & Risk Controlled Daily Trade Plans - newser.com
Measuring Neurocrine Biosciences Inc.’s beta against major indicesPortfolio Risk Summary & Daily Stock Trend Watchlist - newser.com
What data driven models say about Neurocrine Biosciences Inc.’s futureJobs Report & Smart Swing Trading Alerts - newser.com
How to build a dashboard for Neurocrine Biosciences Inc. stockWeekly Market Summary & Expert Approved Momentum Ideas - newser.com
What earnings revisions data tells us about Neurocrine Biosciences Inc.Quarterly Risk Review & Expert Curated Trade Setup Alerts - newser.com
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum - Yahoo Finance
What analysts say about Neurocrine Biosciences Inc stockPrice Volatility Patterns & Small Budget Growth - earlytimes.in
Neurocrine Biosciences to Present at Upcoming Investor Conferences - Your Wyoming Link
Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News - Yahoo Finance
What analysts say about Neurocrine Biosciences Inc NB3 stockSector Performance Review & Free Turn Volatility To Profit - earlytimes.in
Neurocrine’s depression candidate fails mid-stage study but analysis continues - The Pharma Letter
Neurocrine Biosciences (NBIX): Assessing Valuation After Lead Depression Drug Misses Phase 2 Study Goal - simplywall.st
What valuation multiples suggest for Neurocrine Biosciences Inc. stockPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Neurocrine Biosciences fails mid-stage study of depression drug - MSN
Neurocrine Bio Drug Licensed From Takeda Flunks Mid-Stage Test in Depression - MedCity News
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice - sharewise.com
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile - Benzinga
Neurocrine’s Depression Drug Misses In Phase II - Citeline News & Insights
Morgan Stanley Lowers Price Target for Neurocrine Biosciences (N - GuruFocus
Neurocrine Biosciences' Depressive Disorder Drug Fails to Meet Primary Goal in Phase 2 Study - MarketScreener
Neurocrine’s depression drug fails to meet primary endpoint in phase 2 - Investing.com Nigeria
Neurocrine’s depression drug fails to meet primary endpoint in phase 2 By Investing.com - Investing.com South Africa
Neurocrine chalks up a depression drug failure - BioPharma Dive
Neurocrine Biosciences Inc (NBIX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):